EcoR1 Capital

EcoR1 Capital is a San Francisco-based investment advisory firm established in 2012 by Oleg Nodelman, specializing exclusively in the biotechnology sector. The firm operates as a fundamental, research-driven investor, deploying capital into both public and private companies. Its core philosophy revolves around identifying and supporting innovative enterprises that are at the forefront of developing next-generation medicines, reflecting a deep commitment to the life sciences industry.

The firm's investment strategy is characterized by a long-term horizon, emphasizing thorough due diligence and a deep understanding of scientific and clinical advancements. EcoR1 Capital manages a substantial portfolio, with approximately $3.7 billion in regulatory assets under management as of March 31, 2023, underscoring its significant financial capacity. This substantial asset base allows the firm to make meaningful investments across various stages of a company's lifecycle, from late-stage venture rounds to publicly traded equities.

EcoR1 Capital typically engages in later-stage venture capital rounds, including Series B, C, and D, as well as pre-IPO and public market investments. While they participate in syndicated rounds, they also demonstrate the capacity to lead significant financing efforts. A notable example of their lead investment capability is their role in the $250 million Series B round for Centessa Pharmaceuticals. Given their focus on substantial, later-stage biotech companies, their typical first check sizes for private investments generally range from a minimum of $5 million, extending up to $100 million for leading large, strategic rounds. They seek to partner with companies poised for significant clinical and commercial milestones, leveraging their sector expertise to support growth.